July 10, will be presenting at conference. Prur
Post# of 72440
(Total Views: 224)
Posted On: 06/08/2017 11:13:21 AM
July 10, will be presenting at conference.
Prurisol: Phase 2B on track for analysis in 3Q this year. Focusing on PASI 75 at end of study, can make apples to apples comparison with other psoriasis drugs. Have added sites.
Kevetrin: Phase 2A is open. In parallel, have done non-clinical studies to try to get oral formulation. Need to dose it multiple times weekly because of short half-life. Also non-clinical research in other cancers.
AML research done in Italy will be presented this month. (Done by non-company entity)
We are extremely excited -- other clinical developments underway.
Multiple big pharmas continue discussions under CDA. Partnerships remain key focus
Prurisol: Phase 2B on track for analysis in 3Q this year. Focusing on PASI 75 at end of study, can make apples to apples comparison with other psoriasis drugs. Have added sites.
Kevetrin: Phase 2A is open. In parallel, have done non-clinical studies to try to get oral formulation. Need to dose it multiple times weekly because of short half-life. Also non-clinical research in other cancers.
AML research done in Italy will be presented this month. (Done by non-company entity)
We are extremely excited -- other clinical developments underway.
Multiple big pharmas continue discussions under CDA. Partnerships remain key focus
(5)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼